Longevity Biomarker Testing: Beyond Standard Bloodwork
AUTHOR
Aerwell
SHARE
Standard bloodwork paints only a fraction of the picture of your aging trajectory. A normal cholesterol level, normal blood sugar, and normal liver enzymes may satisfy your primary care physician, but they tell you nothing about whether you are aging faster than your chronological age, whether your immune system is in functional decline, or whether silent inflammation is accelerating your cellular deterioration. Longevity biomarker testing bridges this critical gap by measuring the biological processes that actually drive aging—the hallmarks that determine how long you’ll live well, not just how long you’ll live.
What Longevity Biomarker Testing Actually Measures
Longevity biomarkers fall into two complementary categories. Functional biomarkers measure observable physiology that predicts your trajectory of healthspan—inflammation, metabolic health, hormone balance, mitochondrial function, and cellular repair capacity. These are the moving parts of aging; they shift in response to lifestyle changes and reveal which hallmarks of aging are most active in your body right now.
The second category is biological age markers—algorithms that directly calculate your aging rate by synthesizing data across multiple biological systems. Epigenetic clocks like GrimAge and DunedinPACE read chemical modifications on your DNA that shift predictably with age and disease. They answer the question: at the molecular level, how old am I aging?
Here’s the practical difference: imagine a 50-year-old with a GrimAge of 44 and another 50-year-old with a GrimAge of 58. They are the same chronological age but aging at radically different speeds. The first is functionally 6 years younger at the molecular level; the second is 8 years older. And the direction of change matters most. If your GrimAge drops 2 years in 12 months through targeted intervention, that is quantitative evidence that your protocol is working—that you are literally slowing your aging rate.
Aerwell’s longevity biomarker panel measures both functional biomarkers and biological age scores in an integrated framework, allowing us to see the complete picture of your aging rate and the specific drivers that need to be addressed.
Why Standard Bloodwork Misses the Aging Picture
Your primary care physician is trained to identify disease—to find the pathology. Standard bloodwork is optimized for diagnosis, not longevity assessment. The reference ranges are built to separate sick from normal, not optimal from aging. A TSH of 3.5 is ‘normal,’ but it may signal suboptimal thyroid function contributing to metabolic slowdown. An LDL of 130 meets standard guidelines, but particle size and oxidation status—which predict atherosclerosis much better than absolute number—are never tested. A fasting glucose of 105 is technically ‘prediabetic,’ but your glucose tolerance curve (how your blood sugar spikes after meals, how long it takes to recover) is invisible in standard labs.
Most critically, standard bloodwork is static—it photographs one moment in time. It tells you whether you have diabetes, not whether your glucose stability is declining or improving. It doesn’t tell you whether your immune system is aging faster than expected, whether your inflammation profile is accelerating disease risk, or whether your metabolic rate is slowing in a way that will compound into metabolic disease.
The Five Core Categories of Longevity Biomarkers
- Inflammatory & Immune Markers
Chronic low-grade inflammation is a hallmark of aging. It accelerates neurodegeneration, atherosclerosis, sarcopenia, and frailty. Standard CRP (C-reactive protein) is crude; it rises acutely with infection or injury but doesn’t capture the smoldering chronic inflammation that quietly drives aging. Longevity assessment includes:- High-sensitivity CRP (hsCRP)—inflammation at the sub-clinical level
- IL-6 and TNF-alpha—key pro-inflammatory cytokines
- Homocysteine—elevated levels predict cognitive decline and atherosclerosis
- Interleukin-1 receptor antagonist (IL-1ra)—a marker of inflammaging
- White blood cell differential—immune cell ratios that shift with aging
- Metabolic & Glucose Control
Metabolic dysfunction is one of the strongest predictors of accelerated aging. Beyond fasting glucose and HbA1c, longevity assessment measures:- Fasting insulin—often elevated before blood sugar rises, indicating insulin resistance
- Glucose tolerance (2-hour glucose post-challenge)—reveals early glucose dyscontrol
- HOMA-IR (Homeostatic Model Assessment for Insulin Resistance)—calculated ratio
- Metabolic rate and body composition analysis—direct measurement of caloric burn
- Lipid & Cardiovascular Health
Total cholesterol tells almost nothing. Aerwell measures:- LDL particle size and number (NMR lipoprofile)—small dense particles are atherogenic
- HDL and HDL particle count—functional cholesterol management
- Triglyceride-to-HDL ratio—metabolic health indicator
- Lipoprotein(a)—genetic risk factor independent of statin response
- Apolipoprotein B—direct measure of atherogenic particle burden
- Hormonal Status
Hormonal decline is a major axis of aging. Standard hormone panels are superficial. Longevity assessment includes:- Sex hormones (testosterone, estradiol)—anabolic state and tissue repair
- DHEA-S—marker of adrenal reserve and stress resilience
- Cortisol (morning and throughout day)—hypothalamic-pituitary-adrenal axis function
- Thyroid panel (TSH, Free T3, Free T4, thyroid antibodies)—metabolic rate and autoimmunity
- IGF-1—growth hormone axis and anabolic capacity
- Cellular & Mitochondrial Function
These are the emerging frontier of longevity testing:- Lactate—cellular energy production efficiency
- Pyruvate—metabolic substrate utilization
- Amino acid profiles—protein synthesis and cellular repair machinery
- Glutathione (reduced)—master antioxidant status
- CoQ10—mitochondrial energy production cofactor
Longevity Biomarker Reference Panel
| Marker Category | Key Tests | Healthy Range (Longevity Context) | What It Predicts |
|---|---|---|---|
| Inflammatory | hsCRP, IL-6, TNF-alpha | <1.0 mg/L, <2.0 pg/mL | Cognitive decline, atherosclerosis risk |
| Glucose Control | Fasting insulin, 2-hr glucose | Insulin <8 uIU/mL, <120 mg/dL | Diabetes risk, metabolic aging |
| Lipid Profile | LDL particles, HDL, Apo-B | Apo-B <70 mg/dL | Atherosclerosis, CVD mortality |
| Hormonal | Testosterone, DHEA-S, Free T3 | Age-adjusted mid-range | Anabolic capacity, metabolic rate |
| Cellular | Lactate, amino acids, GSH | Optimal ranges vary | Mitochondrial efficiency, aging rate |
Emerging Biomarkers: The Next Frontier in Longevity Testing
DunedinPACE: Measuring the Speed of Aging
DunedinPACE (Pace of Aging Calculated from the Epigenome), developed at Duke University and the University of Otago in 2022, represents a fundamental shift in how we measure aging. While earlier epigenetic clocks like GrimAge calculate biological age at a single moment in time, DunedinPACE measures the pace—the rate—at which you are aging right now. This distinction is critical.
Think of it as the difference between checking your speedometer (DunedinPACE) versus reading your odometer (GrimAge). Your odometer tells you total mileage accumulated; your speedometer tells you whether you’re accelerating, cruising, or slowing down. DunedinPACE’s score of 1.0 means you’re aging at the population average rate. A score of 0.8 means you’re aging 20% slower than expected. A score of 1.2 means you’re aging 20% faster—and on a 60-year lifespan, that compounds into years of lost healthspan.
DunedinPACE has been validated across multiple cohorts and is more sensitive to lifestyle changes than static clocks, making it the most actionable tool for monitoring whether your longevity protocol is actually working. Available through TruDiagnostic’s Aging Phenotype Test.
Proteomics-Based Aging Scores
DNA methylation captures one layer of aging biology. Plasma proteomics captures another. The SomaScan platform measures approximately 7,000 proteins simultaneously—a window into the functional state of every organ and tissue. Proteins shift predictably with aging; they accumulate and decline in predictable patterns. Companies like Alkahest and Human Longevity Inc. have built protein-based aging clocks that identify accelerated aging in specific organ systems (brain, heart, kidneys, liver, immune) before traditional diagnostic tests reveal disease.
Proteomics clocks are more expensive than methylation clocks but provide a different biological signal. A person might have normal GrimAge and accelerated proteomics aging in the brain (high risk of cognitive decline) or heart (high risk of atherosclerosis). Multimodal assessment—combining epigenetic, proteomic, and metabolic data—is the future of precision aging medicine.
Continuous Glucose Monitoring (CGM)
HbA1c, the standard diabetes screening tool, is a 90-day average that hides dangerous glucose variability. You could have an HbA1c of 5.6% and still experience dangerous post-meal glucose spikes to 180+ mg/dL, nocturnal hypoglycemia, and extended periods of time outside the optimal range (70-100 mg/dL). These glucose excursions damage blood vessel endothelium, trigger inflammation, and accelerate aging.
A 2-week continuous glucose monitoring (CGM) wear reveals your actual glucose patterns: post-meal spike amplitude, time-to-peak, recovery slope, nocturnal glucose, and time-in-range metrics far more granular and actionable than any lab value. A 2-week CGM is recommended as part of comprehensive metabolic longevity assessment, especially for anyone with family history of diabetes or metabolic syndrome.
DunedinPACE is increasingly considered the most actionable aging clock because it changes in response to interventions within months—making it a practical tool for monitoring whether your longevity protocol is working.
How Biomarker Results Drive Personalized Protocols
Once results are in hand, interpretation is everything. A longevity medicine specialist doesn’t simply flag ‘abnormal’ values—they identify the rate-limiting steps in your aging. If your DunedinPACE is 1.3 (aging fast) but your inflammatory markers are normal, the problem isn’t inflammation; it’s likely metabolic dysfunction or hormonal decline. If your GrimAge is elevated but your functional markers are excellent, you may be aging faster molecularly but have protective resilience phenotypically. These distinctions drive radically different protocols.
A high inflammatory profile with normal metabolic markers might trigger anti-inflammatory nutrition (omega-3 index, polyphenol density), targeted immune modulation, or microbiome assessment. Elevated insulin with normal glucose points to early insulin resistance—requiring carbohydrate restriction or circadian metabolic optimization. Mitochondrial fatigue (high lactate, low CoQ10) requires energetic support: ketone bodies, mitochondrial precursors, or systemic metabolic optimization. Each person’s biomarker constellation is unique, and so is the intervention strategy.
Retest Frequency and Longitudinal Tracking
A single snapshot of biomarkers is useful; longitudinal tracking is transformative. The question isn’t ‘What am I?’ but ‘What am I becoming?’ Aerwell recommends comprehensive biomarker retesting every 12 months for optimal monitoring, with intermediate DunedinPACE retesting at 6 months if you’re implementing intensive interventions. Faster-moving functional markers (glucose control, inflammation, hormonal status) can shift meaningfully in 3 months; biological age markers shift over 6-12 months.
What matters most is the trajectory. A small decline in DunedinPACE over a year—from 1.1 to 1.0—is meaningful and motivating evidence that your protocol is working. Month-to-month noise is expected; year-over-year trends reveal truth.
How to Find a Longevity Biomarker Testing Provider
Not all biomarker testing is created equal. Direct-to-consumer genetic tests and wellness platforms often cherry-pick attractive metrics while ignoring the biomarkers that actually predict disease and aging. Red flags include: no physician oversight of interpretation, absence of epigenetic or proteomics data, no integration with lifestyle protocols, and positioning as ‘risk screening’ rather than actionable aging assessment.
When evaluating a longevity provider, look for: (1) physician oversight—results interpreted in clinical context, not as data points alone; (2) comprehensive panel including both functional and biological age markers; (3) longitudinal tracking capability and protocol adjustment based on results; (4) integration with personalized intervention development, not just data delivery; (5) access to functional medicine and longevity medicine expertise, not primary care generalists.
Aerwell’s longevity biomarker panel includes inflammatory markers, comprehensive metabolic assessment, lipid phenotyping, hormonal status, epigenetic age (GrimAge and DunedinPACE), optional proteomics, and continuous glucose monitoring assessment when indicated. Results are interpreted in the context of your full clinical picture—genetics, family history, lifestyle data, and prior interventions—to build a targeted protocol that addresses your specific aging rate drivers.
Sources & Further Reading
- Hallmarks of Aging (Lopez-Otin et al., Cell 2013)
- GrimAge: An Epigenetic Clock (Lu et al., Aging Cell 2019)
- DunedinPACE, a DNA methylation biomarker of the pace of aging
- Quantification of biological aging in young adults (PNAS 2015)
- Organ aging signatures in the plasma proteome (Nature 2023)
- Continuous glucose monitoring in real-world data
- Inflammatory markers and aging (Nature Aging 2021)
- Epigenetic clocks and mortality prediction
- Metabolic aging and insulin resistance
- Hormonal status and aging trajectories
- Mitochondrial dysfunction in aging
- Blood biomarkers of aging and disease (Nature Reviews 2022)
- Proteomics of human plasma and lifespan prediction
- DunedinPoAm validation in early-life cohorts
